Evidence map›Paper›PMID 42642458›Full record

ReviewNature reviews. Endocrinology2026

Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.

Sunita M C De Sousa, Cynthia L Andoniadou, Adrian F Daly, Mônica Gadelha, Federico Gatto, Peter Kamenický, Pedro Marques, Martin Reincke, Frederique Ruf-Zamojski, Roberto Salvatori and 14 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sunita M C De SousaSchool of Medicine, Adelaide University, Adelaide, South Australia, Australia. Sunita.DeSousa@sa.gov.au.ORCID http://orcid.org/0000-0003-0127-6482
Cynthia L AndoniadouCentre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0003-4311-5855
Adrian F DalyDepartment of Endocrinology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.ORCID http://orcid.org/0000-0001-6130-2975
Mônica GadelhaNeuroendocrinology Research Center/Endocrinology Division, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Federico GattoDepartment of Internal Medicine and Medical Specialties, Endocrinology Unit, University of Genoa, Genoa, Italy.
Peter KamenickýPhysiologie et Physiopathologie Endocriniennes, Inserm, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Pedro MarquesEndocrinology Department, Pituitary Tumor Unit, Hospital CUF Descobertas, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-4959-5725
Martin ReinckeDepartment of Medicine IV, LMU Hospital, Ludwig Maximilians University, Munich, Germany.ORCID http://orcid.org/0000-0002-9817-9875
Frederique Ruf-ZamojskiPituitary Center, Department of Medicine, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2451-8598
Roberto SalvatoriDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6495-2244
Yutaka TakahashiDepartment of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan.ORCID http://orcid.org/0000-0002-1337-9246
Christina TatsiDepartment of Pediatrics, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Takako ArakiDepartment of Medicine, Division of Diabetes, Endocrinology & Metabolism, University of Minnesota, Minneapolis, MN, USA.
Sabrina ChiloiroDivision of Endocrinology, Metabolic Disease and Internal Medicine, Agostino Gemelli University Hospital IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-9241-2392
Laura DichtelDepartment of Medicine, Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
Adriana G IoachimescuDepartment of Medicine, Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Susana Mallea-GilEndocrinology Division, Hospital Militar Central, Buenos Aires, Argentina.
Dan A NiculescuDepartment of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Alberto M PereiraDepartment of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-1194-9866
Ilan ShimonGray Faculty of Medicine and Health Sciences, Institute of Endocrinology, Tel Aviv University, Tel Aviv, Israel.
John WassDepartment of Endocrinology, Churchill Hospital, Oxford, UK.
Gabriel ZadaDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Maria FleseriuPituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-9284-6289
Shlomo MelmedPituitary Center, Department of Medicine, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2355-3447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic testing of patients with pituitary adenomas enables delivery of genotype-based precision care. Germline testing might identify variants predisposing to formation of pituitary adenomas and, potentially, other neoplasms. These include loss-of-function variants in AIP, MEN1, CDKN1B, PRKAR1A, SDHA, SDHB, SDHC, SDHD and MAX; GPR101-containing Xq26.3 microduplications; and postzygotic gain-of-function GNAS variants. Somatic testing might help identify and manage aggressive pituitary adenoma types and very rarely encountered pituitary carcinomas. This Pituitary Society Consensus Statement provides evidence-based guidance on the clinical application of these genetic tests, focusing on germline genetic testing, with recommendations regarding genes for inclusion in panel testing, test indications, pre-test counselling, test methodologies, and the interpretation and follow-up of results. As somatic genetic testing is gradually becoming available in clinical practice, recommendations are provided regarding clinical scenarios in which somatic testing might be considered and which genes to test. The consensus group concluded that genetic testing is an increasingly valuable adjunct in the assessment and management of people with pituitary adenomas. When indicated, genetic testing should ideally be undertaken within a multidisciplinary team comprising endocrine, genetic and laboratory expertise to ensure high-quality testing and safe and effective result interpretation and follow-up.

Identifiers

PMID42642458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.